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TuberculosisAbstract Aim of the work: Drug resistance surveillance is a useful tool to assess the effective
functioning of tuberculosis (TB) control program. This study was undertaken to know the ﬁrst line
anti tuberculosis drug susceptibility proﬁle of Mycobacterium tuberculosis clinical isolates from the
Gulbarga district of South India.
Methods: Drug susceptibility test was performed for 102 clinical isolates of M. tuberculosis
belonging to new (n= 62), treated (n= 22) and unknown treatment category (n= 18) of TB.
All the isolates were tested for susceptibility to ﬁrst line anti-tuberculosis drugs by minimum
inhibitory concentration (MIC) and resistance ratio method (for streptomycin).
Results: The susceptibility proﬁle ofM. tuberculosis to all ﬁve ﬁrst line anti-tubercular drugs was
found to be 60.78% (62/102). Overall, multi drug resistance (resistance to at least isoniazid and
rifampicin) was observed in 8.82% (9/102) isolates and was found to be higher for treated cases
(18.18%).
Conclusions: High level of drug resistance observed in new cases for isoniazid, rifampicin and
ethambutol suggests need for the implementation of drug resistance surveillance studies in order
to document the success of the tuberculosis control program in reducing the level of drug resistance.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tuberculosis has become a serious health problem since the
emergence of HIV and the increasing appearance of drug resis-
tance strains [1]. Drug resistance in tuberculosis is a global
problem. Levels of drug resistance serve as an epidemiological
indicator to assess the extent of resistant bacterial transmission
in the community. However, information on the level of drugrculosis.
Table 1 General characteristics of participants enrolled in the
study.
Characteristics Total
Sex
Male 76
Female 26
Age group
<30 years 36
31–60 years 59
>60 years 7
Category
New 62
Treated 22
Unknown 18
934 P.R. Abraham et al.resistance is difﬁcult to obtain at the community level, espe-
cially in a large developing country such as India with limited
resources [2]. Although drug resistance surveillance is consid-
ered a useful tool to assess the success of the TB control pro-
gram the facilities to collect specimens and also to perform the
drug susceptibility test (DST) are not readily available in all
parts of the world. Proper collection and transportation of
sputum specimens from remote survey settings to a quality
controlled TB culture laboratory is crucial to ensure accurate
results that can contribute to national and global surveillance
of TB drug resistance [3]. In the present study, an attempt was
made to collect the sputum specimens from tuberculosis
patients attending designated microscopic centers (DMC) of
the Gulbarga district and transport them to a TB culture
laboratory for the study of anti-mycobacterial susceptibility
proﬁles of Mycobacterium tuberculosis to ﬁrst line
anti-tuberculosis drugs.
Materials and methods
Patients and specimens
The study area, Gulbarga district is located in the
north-eastern part of the Karnataka state in India. Sputum
specimens were collected from clinically suspected pulmonary
tuberculosis patients attending DMC and private clinics of this
district. The study was undertaken from February 2005 to
March 2008. The treatment history of the patients was col-
lected from available data at the DMC. The specimens were
collected after obtaining oral consent from the study
participants.
Specimen transport
Sterile screw capped universal containers and preservative,
cetylpyridinium chloride (1%) with 2% Sodium Chloride
(CPC-NaCl) solution was supplied to the DMC for the collec-
tion of sputum. Smear microscopy by Ziehl–Neelsen (ZN)
method was performed on all sputum specimens at the DMC
as per RNTCP guidelines [4]. After smear microscopy, equal
volume of CPC-NaCl was added carefully to the remaining
portion of the sputum; the tightly capped containers were
sealed with paraﬁlm to prevent leakage during transit.
Specimens along with the smear report were transported at
ambient temperature to the National JALMA Institute for
Leprosy and Other Mycobacterial Diseases (NJIL and
OMD), Agra, Uttar Pradesh. The laboratory was accredited
for culture and susceptibility testing.
Isolation and identiﬁcation of M. tuberculosis
The specimens were processed by the method described earlier
[5]. In brief, the specimens were centrifuged at 3000g for
15 min and after decanting the supernatant, the deposit was
resuspended in 1–2 ml of sterile distilled water. A loopful of
the suspension was inoculated onto two plain Lowenstein–Je
nsen’s (LJ) medium slopes containing glycerol and one con-
taining pyruvate [6]. The LJ slopes were incubated at 37 C
and were examined weekly for eight weeks. Mycobacterial
cultures were identiﬁed based on the growth rate, pigment pro-
duction and standard biochemical tests like niacin utilization,nitrate reduction, catalase activity and susceptibility to p-nitro
benzoic acid [7].
Drug susceptibility study
Drug sensitivity test was performed by minimum inhibitory
concentration (MIC) method for rifampicin (R), isoniazid
(H), ethambutol (E) and pyrazinamide (Z) and resistance ratio
(RR) for streptomycin (S) [6,8–11]. The anti-TB drugs were
procured from Sigma Chemical Co., St. Louis, USA,
Novartis India Pvt. Ltd., Mumbai for preparing the drug con-
taining LJ media. In the case of pyrazinamide, the pH of the
medium was adjusted to 5.5 using 1 N HCl. A standard bacte-
rial suspension (4 mg/ml) was used to inoculate on LJ slants
with a loop of 3 mm internal diameter. M. tuberculosis
H37Rv was used as reference susceptible control in every batch
of testing. MIC was determined by using standard criteria of
counting the colony forming units and comparing with culture
controls. MIC is deﬁned as the lowest concentration of the
drug inhibiting the growth of 20 or more colonies at drug con-
centrations (lg/ml) 64, 1, 4, 100 for R, H, E, Z and RR of 8 or
more for S.Results
Drug susceptibility test was performed for 102 M. tuberculosis
isolates recovered from sputum specimens of individuals
attending the DMC of Gulbarga. The specimens were collected
after obtaining oral consent from study subjects with the help
of DMC staff (Table 1). The mean age of the patients was
37.2 ± 13.18 year and the male to female sex ratio was almost
3:1. The drug susceptibility proﬁle for new, treated and
unknown treatment categories is given in Table 2. Overall,
the drug susceptibility pattern showed 60.78% sensitivity to
all the drugs tested and any type of resistance was observed
in 39.21% of the isolates tested. Among any type of resistance,
mono resistance was 25.49% and other pattern of resistance
was 4.9%. Apart from these, multiple drug resistance
(MDR) i.e., M. tuberculosis resistance to at least isoniazid
and rifampicin was also recorded in this study and it was found
to be 8.82% and was highest for previously treated cases
(18.18%). On comparing the number of drugs to which
patients were resistant to, 25.49% patients showed resistance
to one drug and 7.84% of the patients were resistant to two
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Figure 1 Frequency of drug resistance inM. tuberculosis isolates
of Gulbarga. Among the ﬁve anti-TB drugs tested, the number of
drugs to which the patients were resistant to was calculated for 102
M. tuberculosis isolates. It was found that 60.28% of the isolates
showed susceptibility to all the drugs and remaining isolates
showed resistance to one to four drugs; none of the isolates was
found to be resistant to all the ﬁve drugs tested.
Table 2 Drug susceptibility proﬁle of M. tuberculosis in Gulbarga.
Drug susceptibility proﬁle New cases Previously treated Unknown treatment category Total
No. % No. % No. % No. %
Total No. of cases tested 62 100 22 100 18 100 102 100
Sensitive to all ﬁve drugs 38 61.29 11 50 13 72.22 62 60.78
Any resistance 24 38.70 11 50 5 27.77 40 39.21
Isoniazid (H) 10 16.12 7 31.81 4 22.22 21 20.6
Rifampicin (R) 7 11.29 5 22.72 3 16.66 15 14.70
Ethambutol (E) 10 16.12 4 18.18 2 11.11 16 15.68
Pyrazinamide (Z) 5 8.06 3 13.63 1 5.55 9 8.82
Streptomycin (S) – – 2 9.09 – – 2 1.96
Mono resistance 17 27.41 7 31.81 2 11.11 26 25.49
Isoniazid (H) 5 8.06 3 13.63 2 11.11 10 9.80
Rifampicin (R) 2 3.22 1 4.54 – – 3 2.94
Ethambutol (E) 7 11.29 1 4.54 – – 8 7.84
Pyrazinamide (Z) 3 4.83 2 9.09 – – 5 4.90
Multi drug resistance 3 4.83 4 18.18 2 11.11 9 8.82
H+ R 3 4.83 1 4.54 – – 4 3.92
H+ R+ E – – – – 2 11.11 2 1.96
H+ R+ E+ S – – 2 9.09 – – 2 1.96
H+ R+ E+ Z – – 1 4.54 – – 1 0.98
Other patterns 4 6.45 – – 1 5.55 5 4.90
H+ E 1 1.61 – – – – 1 0.98
H+ S – – – – – – – –
H+ Z 1 1.61 – – – – 1 0.98
R + E 1 1.61 – – – – 1 0.98
R + E+ Z 1 1.61 – – – – 1 0.98
R + Z – – – – 1 5.55 1 0.98
Note: The combination of drugs which is not mentioned in this table had 0% resistance.
Drug susceptibility proﬁles of Mycobacterium tuberculosis isolates 935drugs while, 2.94% of patients were resistant to three and four
drugs. However, none of the isolates was totally resistant to all
the ﬁve drugs tested in this study (Fig. 1).
Discussion
The level of drug resistance is known to provide an epidemio-
logical indicator to assess the extent of resistant bacterial
transmission in the community as well as success of the TB
control program. In the present study we have made an attempt
to know the drug susceptibility proﬁle ofM. tuberculosis among
different categories of TB patients in Gulbarga.
The drug susceptibility proﬁles ofM. tuberculosis among the
new cases showed susceptibility to S for all the isolates tested
where as it was observed to be 13.7% in Hooghly [12] and
almost 15% in Wardha district, which was reported to be the
highest among the studies conducted in India [13]. The pattern
of resistance to H was 16.12% while the resistance reported
from the Kolar district of the same state was almost double
(32.9%) [14]. The resistance pattern for R and E was observed
to be higher in this study (11.29% and 16.12% respectively) as
compared to similar studies conducted in India [15]. Hence,
care should be taken to prevent the development of drug resis-
tance when handling new cases of TB during the course of treat-
ment. MDR was also observed in new cases and it was 4.83%.
However; highest percentage of MDR (13.2%) in India was
reported from Lucknow during the study conducted in between
2000 and 2002 with a sample size of 318 [16].
Among the previously treated cases, it is interesting to note
that other pattern of resistance was not observed. The isolatesexhibited either mono or multiple drug resistance patterns. On
the other hand, resistance observed was higher for H and R
(31.81% and 22.72% respectively) and resulted in prevalence
of MDR. Regarding prevalence rate of MDR, the literature
from India and other developing Asian countries shows a wide
936 P.R. Abraham et al.variation. According to the WHO fourth Global Project [17],
prevalence rate of MDR-TB among previously treated cases
in India is 17. 2%; while, we observed 18.18% which is compa-
rable to previous Indian studies (14–49%) [18]. It is also
observed that among the MDR, half of the isolates (9%)
showed resistance to all four antitubercular drugs
(H + R+ E+ S) tested in this study which indicates the fail-
ure of ATT. Hence, preventive measures such as motivating
the patients for strict adherence to the prescribed drug therapy
and also avoiding the shifting of treatment are essential.
The treatment category of 18 patients was unknown as the
specimens from these patients were collected from private
diagnostic centers and hence, they were separately categorized.
However, the drug resistance pattern of this category shows
higher resistance to H and R and also MDR was observed
in this category which resembles the susceptibility proﬁle of
previously treated cases suggesting that the patients belonging
to this category might have received ATT and discontinued the
therapy. Hence, treatment history of the patients should be
properly collected before the initiation of ATT for appropriate
treatment and also to avoid misuse of the drugs.
When considering the overall specimens tested in this
study, the combined resistance for any drug and multiple
drugs was observed to be higher than that reported in
Raichur, a neighboring district of Gulbarga where drug
resistance survey was conducted in 1999 [19]. Although,
RNTCP was implemented in Gulbarga during 2000, poor
personal as well as public health awareness may increase
the incidence of most infectious diseases including tuberculo-
sis. New smear positive case detection rate and treatment
success rate shows this district is far from reaching the glo-
bal target set by WHO (new smear positive case detection
rate P70% and treatment success rate of P85%). The
emergence of drug resistance in M. tuberculosis isolates of
this area may be due to any of the factors described by
Paramasivan et al. [20]. Hence, considering the population
of Gulbarga and also migration of people to other states,
drug resistance survey in this district will be helpful in effec-
tive management of TB. This study also demonstrates that
the specimens from this area can be transported to any
Indian reference laboratories for undertaking the drug resis-
tance surveillance in this part of the country.
The major limitation of this study is the number of samples
included in each category which is due to the insufﬁcient data
collection. The isolates grouped under UTC showed the pat-
tern of resistance which is similar to treated cases. Another
limitation of this study is the methodology followed for
DST. Generally for drug resistance surveys the proportion
method is followed. However, this is a preliminary study and
our intention was to study the drug susceptibility proﬁle of
M. tuberculosis to ﬁrst line anti TB regimens. This information
will serve as useful baseline data in future studies.Source of support
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